Provided by Tiger Fintech (Singapore) Pte. Ltd.

Voyager Therapeutics

3.20
0.0000
Post-market: 3.210.0085+0.27%16:44 EDT
Volume:303.24K
Turnover:971.35K
Market Cap:177.08M
PE:-2.19
High:3.28
Open:3.20
Low:3.17
Close:3.20
Loading ...

Voyager Therapeutics, Inc. (VYGR): A Cheap Biotech Stock to Invest In Now

Insider Monkey
·
12 Feb

Voyager Therapeutics price target lowered to $12 from $14 at Wells Fargo

TIPRANKS
·
12 Feb

Wedbush Adjusts Price Target on Voyager Therapeutics to $9 From $11, Maintains Outperform Rating

MT Newswires Live
·
12 Feb

Voyager Therapeutics Shares Fall After Dropping Plan for VY9323 IND Filing in Mid-2025

MT Newswires Live
·
11 Feb

Voyager Therapeutics to Assess 'Alternative Payloads' for ALS Gene Therapy Program

Dow Jones
·
11 Feb

Voyager Therapeutics Inc - Estimates Cash Runway Into Mid-2027

THOMSON REUTERS
·
11 Feb

Voyager Therapeutics Inc - to Assess Alternate Payloads for Sod1 ALS Program

THOMSON REUTERS
·
11 Feb

Voyager Therapeutics Inc - Will Not File Ind or Cta for Vy9323 in Mid-2025

THOMSON REUTERS
·
11 Feb

Voyager Therapeutics Inc - Cash Runway Expected to Extend Into Mid-2027

THOMSON REUTERS
·
11 Feb

Voyager Therapeutics Inc - to Assess Alternate Payloads for Sod1 ALS Gene Therapy

THOMSON REUTERS
·
11 Feb

Voyager Therapeutics Inc - Expects Ind Filings in 2025 for Gba1 and Fa, 2026 for Vy1706

THOMSON REUTERS
·
11 Feb

Voyager Therapeutics Inc - No Longer Anticipates Ind Filing for Vy9323 in Mid-2025

THOMSON REUTERS
·
11 Feb

Voyager Provides Update on Sod1 ALS Gene Therapy Program

THOMSON REUTERS
·
11 Feb

Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference

GlobeNewswire
·
06 Feb

What Makes Voyager Therapeutics (VYGR) a New Buy Stock

Zacks
·
31 Jan

Voyager Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
27 Jan

Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

Zacks
·
24 Jan

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate

Zacks
·
23 Jan

REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA

Zacks
·
23 Jan

J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use

Zacks
·
23 Jan